CN109966329A - A kind of application of star extract in treatment acpuei pharyngitis - Google Patents
A kind of application of star extract in treatment acpuei pharyngitis Download PDFInfo
- Publication number
- CN109966329A CN109966329A CN201910415493.8A CN201910415493A CN109966329A CN 109966329 A CN109966329 A CN 109966329A CN 201910415493 A CN201910415493 A CN 201910415493A CN 109966329 A CN109966329 A CN 109966329A
- Authority
- CN
- China
- Prior art keywords
- star
- parts
- application
- treatment
- acpuei pharyngitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a kind of application of star extract in treatment acpuei pharyngitis, belong to technical field of pharmaceuticals, star extract and dexamethasone are demonstrated as effective active composition when treating acpuei pharyngitis by test, with significant synergistic function, and toxic side effect is small, quality is stablized, and treatment total effective rate reaches 100%.
Description
Technical field
The answering in treatment acpuei pharyngitis the present invention relates to technical field of pharmaceuticals more particularly to a kind of star extract
With.
Background technique
Acpuei pharyngitis is pharyngeal common infectious diseases.Acpuei pharyngitis is clinical common pharyngeal illness, can be by virus
Infection, physical chemical factor etc. cause, and early stage is mostly virus infection, later can concurrent bacterial infection.Clinical initial stage shows as swallowing
Dry, itch, hypodynia, burning heat sensation and foreign body sensation, then pharyngeal pain is unbearably.In recent years since rhythm of life is accelerated, social pressures
Increase, in addition living environment is worsening, the disease incidence of the disease is gradually risen.The disease pathogenic factor is more, it is difficult to and it is definite to hold,
Pathogenesis is also without specific final conclusion, therefore clinic is without unified therapeutic scheme and curative effect judging standard.It is clinically at present to adopt more
It is treated with antibiotic, but is largely frequently easy to produce drug resistance and side effect using antibiotic, acpuei pharyngitis is caused to turn
Become chronic pharyngitis, protracted course is refractory, seriously affects the physical and mental health of patient.For caused by neutralizing chemicals prolonged application
Drug resistance and side effect, to overcome the above drawback, the applicant is proposed a kind of star extract and is being controlled by practical exploration
Treat the application in acpuei pharyngitis.
Summary of the invention
The object of the present invention is to provide a kind of application of star extract in treatment acpuei pharyngitis.
The application is that star extract is pharmaceutically acceptable as effective active composition addition with dexamethasone
Auxiliary material drug is traditionally made, be applied to treatment acpuei pharyngitis in.
The weight ratio of star extract and dexamethasone is 17:7 in the drug.
The content of effective active composition is controlled in the drug between 5-9%.
The preferred embodiment for preparing drug are as follows: 17 parts of star extract, 7 parts of dexamethasone, 160 parts of starch, phosphoric acid
60 parts of calcium, 20 parts of ethyl cellulose, 20 parts of croscarmellose sodium, 2 parts of magnesium stearate, is slided 70 parts of hydroxypropyl cellulose
2 parts of mountain flour, 8 parts of mannitol.
Preparation method: by star extract, dexamethasone, mannitol, croscarmellose sodium, starch, phosphoric acid
Calcium sieves with 100 mesh sieve uniformly mixed, hydroxypropyl cellulose is added, soft material granulation is made in ethyl cellulose and suitable water, and 20-30 DEG C
Drying, 30 mesh sieves, then tabletting is uniformly mixed with the calcium stearate of recipe quantity, talcum powder to get drug of the invention.
The star method for preparing extractive: adding appropriate determining alcohol into star is 70% ethyl alcohol, refluxing extraction 3
It is secondary, 2 hours every time, ethyl alcohol is recovered by filtration, is concentrated and dried to obtain the final product.
The star be Saxifragaceae herbaceos perennial, up to 50 centimetres；It is sweet to be distributed in northeast, North China and Shaanxi
The ground such as respectful, Qinghai；It is born in hillside, Lin Bian, gully；Brown has most fibrous roots.Stem is cylindrical, has vertical rib, matter is crisp, frangibility, base
Leave brown, mostly broken, intact leaf is in oval or heart, full edge, and petiole is longer.
The invention has the advantages that: yet there are no the report for sharing star extract and dexamethasone or record, more have no
It is used to treat report or the record of acpuei pharyngitis after star extract and dexamethasone are shared, is star in the present invention
One new purposes of extract, can not only improve curative effect, decrease the usage amount of dexamethasone, while fill in rice with reducing
The toxic side effect of pine, the two act synergistically with synergy, and using conveniently, safely.
Drug of the present invention is to acpuei pharyngitis rat model anti-inflammatory effect
Experimental animal and experimental situation healthy mice 60, SPF grades, 20~24g of weight, half male and half female, sub-cage rearing, by mountain
Eastern university's Experimental Animal Center provides；SD rat 30, SPF grades, 190~205g of weight, half male and half female, sub-cage rearing, by by
Shandong University's Experimental Animal Center provides.Mouse, the raising of rat conventional adaptation start to test after a week.Environment temperature 20~26
DEG C, relative humidity 50%~60%.
Mouse is randomly divided into 3 groups by mouse ear swelling model experiment, every group 20, i.e. model control group, treatment group, sun
Property control group；Drug 0.1g/kg of the invention is given in treatment group's stomach-filling, Amoxicillin 0.3g/kg is given in positive controls stomach-filling,
The isometric distilled water of model control group stomach-filling, administered volume are 10 mL/kg, 1 time a day, continuous 4d.After the last administration
2h puts to death mouse after dimethylbenzene 20 μ L, 0.5h are respectively smeared in each group mouse left ear auricle front and back sides, identical in left and right ear auricle
Position is punched with 4.5mm punch, and using the weight of the left and right auricle of electronic balance weighing, the weight difference of left and right auricle is
Swelling.
Rat toes swelling model tests SD rat 30, and half male and half female is randomly divided into 3 groups, every group 10, i.e. model
Control group, treatment group, positive controls；Drug 0.1g/kg of the invention is given in treatment group's stomach-filling, positive controls stomach-filling is given
Amoxicillin 0.3g/kg, the isometric distilled water of model control group stomach-filling, administered volume are 10 mL/kg, 1 time a day, even
Continuous administration 5d.In the ankle marking of each group rat before administration, using the left and right of toes analyzer measurement each group rat
The volume of parapodum toe is as the toes volume before administration.10% 50 μ L of egg white is injected in each group rat by 1h after the last administration
Left and right sides toes are subcutaneous, and 2,4h measures the volume of rat or so toes after detection administration.
Acpuei pharyngitis animal model experiment SD rat 40, half male and half female is randomly divided into 4 groups, every group 10, sets respectively
For Normal group, model control group, treatment group, positive controls.In addition to Normal group, remaining 3 groups are sprayed using larynx
Day with fog 3 is pressed, each 1 time of the daily morning, afternoon, continuous 3d prepares rat acute by spraying every time to the ammonium hydroxide of the pharyngeal spray 15% of animal
Pharyngitis model.The 4th day after modeling, the drug stomach-filling of the present invention of 0.1g/kg dosage is given by treatment group；Positive controls are given
The Amoxicillin stomach-filling of 0.3g/kg dosage, each group administered volume are 10mL/kg, and Normal group is given respectively with model control group
Isometric distilled water is given, 1 time a day, successive administration 7d.After last dose 1h, etherization rat, abdominal aorta blood sampling
5mL, centrifugation, take serum to be packed as 3 pipes, with kit detection IL-1 β, IL-6, TNF-α content.
Experimental result
Experimental result shows that the mouse ear swelling that drug paraxylene of the invention induces has significant inhibiting effect.Wherein, with
Model control group is compared, and mouse ear swelling degree significantly reduces after drug of the invention is given by treatment group, with model control group ratio
Relatively there is significant difference；The dose effect of drug 0.1g/kg of the invention is given significantly better than Amoxicillin 0.3g/kg by treatment group
Dose effect, concrete outcome see the table below
| Group | Dosage (g/kg) | Swelling (g) |
| Model control group | _ | 3.11±0.36 |
| Treatment group | 0.1 | 0.42±0.12 |
| Positive controls | 0.3 | 1.68±0.51 |
Experimental result shows that the drug in treatment group has the inhibition of highly significant to make the rat toes swelling that egg white induces
With；Compared with model control group, positive controls, 2,4h, there is significant difference after administration；Drug in positive controls is to chicken
The rat toes swelling of egg white induction has inhibiting effect, and compared with model control group, 2,4h, variant after administration, but difference
It is unobvious.
Influence of the drug of the present invention to egg white induced rat toes swelling thickness.
Influence to acpuei pharyngitis rat model is the results show that the drug in treatment group can significantly reduce rat model
- 1 β of serum IL, IL-6, TNF-α content, treatment group and model control group, positive control comparative group have significant difference.
| Group | Dosage (g/ml) | IL-1 β (ng/ml) | IL-6(ng/ml) | TNF-α (ng/ml) |
| Normal group | - | 105.88±21.32 | 26.35±12.54 | 77.69±9.36 |
| Model control group | - | 235.62±38.46 | 101.14±22.65 | 114.23±22.69 |
| Treatment group | 0.1 | 122.68±20.31 | 35.69±19.32 | 79.65±18.75 |
| Positive controls | 0.3 | 148.36±34.26 | 45.68±20.78 | 86.56±22.45 |
Clinical data
1, the early stage acpuei pharyngitis patient 160 that general information selects accept for medical treatment our hospital's in March, 2014 in July, 2016 is as grinding
Study carefully object, male 98 in selected patient, female 82, the age is 42 years old average.Body temperature >=39 DEG C are excluded, the course of disease is more than suppuration in 3 days
Property pharyngitis patient, exclusion used antibiotic medication person and pharyngeal the infected as caused by systemic disease.160 patients
It is randomly divided into treatment group, control group, observation group, prevention and treatment group, every group of 40 patients, each group patient is in gender, age and state of an illness etc.
Compare no difference of science of statistics in terms of general information, is comparable.
2, on the basis of patient knows and is voluntary, patient is divided into 4 groups by us；Taking drug therapy of the present invention is
Treatment group；It only uses star extract as active constituent, is treated according to drug made of the preparation method in the present invention
It is observation group；It only uses dexamethasone as active constituent, is treated according to drug made of the preparation method in the present invention
It is prevention and treatment group；It is control group with amoxicillin tablets treatment.0.5g of adult dosage in each group, every 6~8 hours 1 time, respectively
Group after one week treatment, observes treatment results.
3, criterion of therapeutical effect is fully recovered: pharyngalgia, drying and foreign body sensation symptom completely disappear, and pharyngeal mucosa restores normal；It is effective:
Pharyngalgia, drying and foreign body sensation symptom disappear substantially, and pharyngeal mucosa acute congestion subsides；It is invalid: above-mentioned symptom without change, it is pharyngeal still
It is congested.
4, observation item includes symptom: pharyngalgia, pharyngoxerosis sense, and dysphagia foreign body sensation breathes out to cough, expectoration, fever etc.；Body
Sign: pharyngeal mucosa is congested, and lateral pharyngeal band is congested, swelling, swallows the hyperemia swelling of exudate tonsillotome, surface pus point, and submandibular lymph nodes swells
Big and tenderness etc..
5, treatment results such as following table
| Group | Columns | Recovery from illness | It is effective | In vain | Side effect | Total effective rate (%) |
| Treatment group | 40 | 32 | 8 | 0 | 0 | 100 |
| Observation group | 40 | 4 | 7 | 29 | 8 | 27.5 |
| Prevention and treatment group | 40 | 1 | 12 | 27 | 6 | 32.5 |
| Control group | 40 | 11 | 14 | 15 | 3 | 62.5 |
By the above clinical data it is found that treatment group achieves ideal therapeutic effect, total effective rate is not only higher than control group, also
Higher than the sum of observation group and prevention and treatment group total effective rate, more the good news is toxicity reduces, have no toxic side effect appearance, it can thus be appreciated that this hair
Star extract and dexamethasone in bright drug have synergistic function.
Specific embodiment
The object of the present invention is to provide a kind of application of star extract in treatment acpuei pharyngitis, the application is
Pharmaceutically acceptable auxiliary material is added as effective active composition with dexamethasone in star extract to be traditionally made
Drug is applied in treatment acpuei pharyngitis.The weight ratio of star extract and dexamethasone is 17:7 in the drug；It is described
The content of effective active composition is controlled in drug between 5-9%.The preferred embodiment for preparing drug are as follows: star extract
17g, dexamethasone 7g, starch 160g, calcium phosphate 60g, hydroxypropyl cellulose 70g, ethyl cellulose 20g, cross-linked carboxymethyl are fine
Tie up plain sodium 20g, magnesium stearate 2g, talcum powder 2g, mannitol 8g.Preparation method: by star extract, dexamethasone, sweet dew
Alcohol, croscarmellose sodium, starch, calcium phosphate sieve with 100 mesh sieve uniformly mixed, addition hydroxypropyl cellulose, ethyl cellulose
Soft material granulation, 25 DEG C of drying, 30 mesh sieves are made in plain and suitable water, then mix with the calcium stearate of recipe quantity, talcum powder
Uniform tabletting is to get drug of the invention.The star method for preparing extractive: into star plus appropriate determining alcohol is
70% ethyl alcohol refluxing extraction 3 times, 2 hours every time, is recovered by filtration ethyl alcohol, is concentrated and dried to obtain the final product.
Claims (6)
1. a kind of application of star extract in treatment acpuei pharyngitis, it is characterised in that the application is to mention star
It takes object and dexamethasone that pharmaceutically acceptable auxiliary material is added as effective active composition and drug is traditionally made, be applied to
It treats in acpuei pharyngitis.
2. a kind of application of the star extract according to claim 1 in treatment acpuei pharyngitis, it is characterised in that institute
Stating the weight ratio of star extract and dexamethasone in drug is 17:7.
3. a kind of application of the star extract according to claim 1 in treatment acpuei pharyngitis, it is characterised in that institute
It states and controls the content of effective active composition in drug between 5-9%.
4. a kind of application of the star extract according to claim 1 in treatment acpuei pharyngitis, it is characterised in that institute
State the preferred embodiment for preparing drug are as follows: 17 parts of star extract, 7 parts of dexamethasone, 160 parts of starch, 60 parts of calcium phosphate, hydroxypropyl
70 parts of base cellulose, 20 parts of ethyl cellulose, 20 parts of croscarmellose sodium, 2 parts of magnesium stearate, 2 parts of talcum powder, sweet dew
8 parts of alcohol.
5. a kind of application of the star extract according to claim 1 in treatment acpuei pharyngitis, it is characterised in that institute
The process for preparing medicine stated: by star extract, dexamethasone, mannitol, croscarmellose sodium, starch, phosphoric acid
Calcium sieves with 100 mesh sieve uniformly mixed, hydroxypropyl cellulose is added, soft material granulation is made in ethyl cellulose and suitable water, 25 DEG C of bakings
It is dry, 30 mesh sieves, then it is uniformly mixed tabletting with the calcium stearate of recipe quantity, talcum powder to obtain the final product.
6. a kind of application of the star extract according to claim 1 in treatment acpuei pharyngitis, it is characterised in that institute
State the preparation method of star extract: into star plus ethyl alcohol that appropriate determining alcohol is 70%, refluxing extraction 3 times, every time 2
Hour, ethyl alcohol is recovered by filtration, is concentrated and dried to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910415493.8A CN109966329A (en) | 2019-05-18 | 2019-05-18 | A kind of application of star extract in treatment acpuei pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910415493.8A CN109966329A (en) | 2019-05-18 | 2019-05-18 | A kind of application of star extract in treatment acpuei pharyngitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109966329A true CN109966329A (en) | 2019-07-05 |
Family
ID=67073711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910415493.8A Pending CN109966329A (en) | 2019-05-18 | 2019-05-18 | A kind of application of star extract in treatment acpuei pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966329A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113413402A (en) * | 2021-08-02 | 2021-09-21 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375746A (en) * | 2017-08-02 | 2017-11-24 | 四川金堂海纳生物医药技术研究所 | It is a kind of effectively to treat decoction medicine of chronic pharyngitis and preparation method thereof |
| CN108743697A (en) * | 2018-09-06 | 2018-11-06 | 沂南县众友中药材种植专业合作社 | A kind of application of littleleaf indianmulberry root and stem extract in treating acute viral pharyngitis |
-
2019
- 2019-05-18 CN CN201910415493.8A patent/CN109966329A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375746A (en) * | 2017-08-02 | 2017-11-24 | 四川金堂海纳生物医药技术研究所 | It is a kind of effectively to treat decoction medicine of chronic pharyngitis and preparation method thereof |
| CN108743697A (en) * | 2018-09-06 | 2018-11-06 | 沂南县众友中药材种植专业合作社 | A kind of application of littleleaf indianmulberry root and stem extract in treating acute viral pharyngitis |
Non-Patent Citations (2)
| Title |
|---|
| 樊绍钵等: "《吉林药材图志续集》", 31 March 1995 * |
| 王陵等: "地塞米松对急性咽炎的治疗作用研究", 《河北医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113413402A (en) * | 2021-08-02 | 2021-09-21 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20200024185A (en) | Pharmaceutical and food composition for treating or alleviating influenza a | |
| TW201125568A (en) | Use of antrodia camphorata for treating diseases | |
| CN109966329A (en) | A kind of application of star extract in treatment acpuei pharyngitis | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN109394746A (en) | Ethyl sulfuric acid ammonium is in preparation for preventing or treating the application in diseases associated with inflammation drug | |
| CN100525792C (en) | Chinese medicine composition for treating angiitis and phlebitis | |
| SE516468C2 (en) | Use of an extract from Morinda citrifolia L. for the preparation of drugs for the treatment of tinnitus. | |
| KR20160074719A (en) | Composition comprising extract of Althaea rosea or Atractylodes japonica for the prevention, treatment or improvement of pain | |
| KR20210097487A (en) | Composition for preventing, improving or treating sleep disorders comprising fucoidan | |
| CN106266959A (en) | A kind of compound recipe lotion treating plantar wart | |
| CN109568375A (en) | Application of the sedum lineare n-butanol extract in preparation treatment chronic pain drug | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| CN108403806A (en) | One kind manufactured masticatory pattern medical product and its application based on semen armeniacae amarae | |
| CN111467408B (en) | Traditional Chinese medicine composition for clearing heat and removing toxicity, nourishing yin and reducing fire and preparation method thereof | |
| CN114177163B (en) | Medicine for treating hypertension | |
| CN110420209B (en) | Pharmaceutical composition for treating diabetic peripheral neuralgia and application thereof | |
| CN104000919A (en) | Traditional Chinese medicine composition | |
| CN108378357A (en) | A kind of dietotherapy powder and preparation method thereof for eliminating late tumor pain | |
| CN106902175A (en) | A kind of Chinese medicine ointment for treating perianal eczema | |
| CN104623204B (en) | A kind of Chinese medicine for treating sciatica | |
| TWI421086B (en) | Pharmaceutical composition for treating or releiving inflammatory bowel disease | |
| CN103006827A (en) | Sniffing medicine for treating tuberculosis and preparation method thereof | |
| CN104127613A (en) | Traditional Chinese medicine preparation and caring method for treating child Tourette syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |